Sato Toshihiro, Takahashi Yoshifumi, Imai Michitaka, Isokawa Osamu
Dept. of Gastroenterology and Hepatology, Kashiwazaki General Hospital and Medical Center.
Gan To Kagaku Ryoho. 2016 Jan;43(1):73-7.
Administration of chemotherapy treating hepatocellular carcinoma (HCC) is divided into hepatic arterial infusion chemotherapy (HAIC) which delivers chemotherapeutic agents directly using a catheter, and systemic chemotherapy including oral treatment. Evidence for treatment with sorafenib has emerged indicating it is an effective drug for advanced HCC. HAIC can provide high anticancer efficacy, and it is often performed on patients with advanced HCC in our country. Since various HAIC regimens exist, the efficacy of HAIC using a reservoir system was tested in patients with advanced HCC. The overall response rate was 36%, with a median survival time of 11.9 months. Patients with controlled disease at 8 weeks had Child-Pugh classification A, and no increase in AFP levels when starting early stage in treatment, which were considered to be factors that influenced therapeutic efficacy. Comparison with other HAIC regimens, and consideration of combined treatments using sorafenib and HAIC will be needed.
治疗肝细胞癌（HCC）的化疗分为肝动脉灌注化疗（HAIC），即使用导管直接输送化疗药物，以及全身化疗，包括口服治疗。索拉非尼治疗的证据已经出现，表明它是治疗晚期HCC的有效药物。HAIC可以提供高抗癌疗效，在我国它常用于晚期HCC患者。由于存在各种HAIC方案，因此在晚期HCC患者中测试了使用储液器系统的HAIC的疗效。总缓解率为36%，中位生存时间为11.9个月。在治疗早期开始时，8周时疾病得到控制的患者Child-Pugh分级为A，且甲胎蛋白水平无升高，这些被认为是影响治疗效果的因素。需要与其他HAIC方案进行比较，并考虑索拉非尼与HAIC联合治疗。
